You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Merck
AstraZeneca
Mallinckrodt

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,278,961

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,278,961 protect, and when does it expire?

Patent 9,278,961 protects ERIVEDGE and is included in one NDA.

This patent has fifty patent family members in twenty-four countries.

Summary for Patent: 9,278,961
Title:Pyridyl inhibitors of hedgehog signalling
Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: ##STR00001## wherein A, X, Y R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n are as described herein.
Inventor(s): Gunzner; Janet L. (Berkeley, CA), Sutherlin; Daniel (South San Francisco, CA), Stanley; Mark S. (Pacifica, CA), Bao; Liang (San Mateo, CA), Castanedo; Georgette M. (Redwood City, CA), Lalonde; Rebecca L. (Berkeley, CA), Wang; Shumei (Foster City, CA), Reynolds; Mark E. (Millbrae, CA), Savage; Scott J. (Burlingame, CA), Malesky; Kimberly (San Francisco, CA), Dina; Michael S. (Daly City, CA), Koehler; Michael F. T. (Palo Alto, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA) CURIS, INC. (Lexington, MA)
Application Number:12/960,609
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,278,961

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes   Start Trial   Start Trial METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,278,961

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 532768   Start Trial
Australia 2005282722   Start Trial
Australia 2011201229   Start Trial
Australia 2013219216   Start Trial
Australia 2016203958   Start Trial
Australia 2017261491   Start Trial
Australia 2019226273   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.